Rohde & Schwarz Asia Pte. Ltd.
Overview
Rohde & Schwarz develops, produces and markets a wide range of electronic capital goods for industry, infrastructure operators and government customers. The independent group is among the technology and market leaders in all of its business fields, including wireless communications and RF test and measurement, broadcast and media, air traffic control and military radiocommunications, cybersecurity and network technology.
In fiscal year 2021/2022, Rohde & Schwarz generated EUR 2.53 billion in revenue. The company owes this tremendous success to its 13,000 highly qualified employees in over 70 countries.
Temasek International Private Limited.
Overview
Temasek is a global investment company headquartered in Singapore. It is an active investor and shareholder, delivering sustainable value over time. It is a forward looking institution, acting with integrity and committed to the pursuit of excellence. It is also a trusted steward striving for the advancement of communities across generations.
Temasek's investment philosophy is underpinned by four investment themes:
- Transforming Economies
- Growing Middle Income Populations
- Deepening Comparative Advantages
- Emerging Champions
I am currently Vice President, Strategic Development in Temasek International Private Limited. Our investment focus is in early stage deep technology ventures in the areas of NetZero Technologies, Future of Compute and Cognition and Disruptive Materials. We invest at the late seed stage to Series B, TRL 4-7, pre-revenue companies.
A*STAR Science and Engineering Research Council (SERC)
Overview
I headed the Chemicals, Materials and GreenTech Research Cluster from December 2015 to November 2020. In terms of my organizational role, I supported A*STAR Senior Management to organize the funding and research activities of 4 of A*STAR's research institutes (IMRE and ICES) overseeing 600 research staff and combined budget of >SGD$100M and competitive research programmes with a combined budget of >SGD$150M. I am also involved in research programme ideation, development and implementation and review. These require me to don the role of Futurist, Strategist and Activist, as I will explain below.
MTI Research and Enterprise Division (RED)
Overview
I was seconded to MTI from A*STAR for a period of 1 year between December 2014 to December 2015. Under the RED division, I worked in the R&D department, which oversaw both A*STAR and coordinated national policy for research leading to economic outcomes.
My main role in MTI was to help coordinate the strategic planning for RIE2020 for research with economic outcomes. RIE2020 was announced in January 2016, with the Singapore Government committing SGD$19.1B towards research from 2016 to 2020. This amounts to 1% of GDP investment in RIE.
My other main role was to assist in S&T policy communications. The main mode of policy communication was through speeches for political office holders, which I helped to draft.
A*STAR Biomedical Research Council (BMRC)
Overview
I was seconded to BMRC from the Institute of Materials Research and Engineering (IMRE) in October 2012, for an initial 7 months before I was fully transferred over in May 2013.
My first role in BMRC was in SP where I was in charge of SGD$400mil of competitive funding. I established polices and processes for the governance of this funding, in collaboration with the Economic Development Board (EDB). I was also responsible for outreach to other research performers in the biomedical research space in Singapore.
After SP was transitioned into the Grants Administration Division, I was transferred to the Planning Division in BMRC. My main role here was in corporate planning, and to ensure that funding and resources were available to the BMRC research institutes.
I also spent some time in the Pharmbio cluster in BMRC, overseeing the competitive funding (>SGD$100M) and developing new research programmes for the research institutes in this cluster.